Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
European Thyroid Journal · 2025
DOI: 10.1530/etj-25-0097 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Jan Taprogge und 19 weiteren Autor:innen. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Thyroglobulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Euratom Research and Training Programme.
Abstract (Originalsprache)
Objective
Serum thyroglobulin measurements are used in the long-term management of patients with differentiated thyroid cancer following thyroidectomy and radioiodine therapy. The use of predictive biomarkers, such as post-operative stimulated thyroglobulin levels and absorbed dose, may help to identify patients at risk of disease recurrence or an unsuccessful initial treatment.
Methods
Differentiated thyroid cancer patients treated with 1.1 or 3.7 GBq of radioiodine using recombinant human thyrotropin stimulation or thyroid hormone withdrawal were recruited into observational clinical studies in France, Germany and the UK with aligned study endpoints (MEDIRAD). The maximum absorbed dose to the thyroid remnant was determined and compared to post-operative stimulated thyroglobulin with respect to its ability to predict ablation success. Radioiodine therapy success was defined as unstimulated or stimulated thyroglobulin level of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Jan Taprogge, Glenn Flux
Förderung
- Euratom Research and Training Programme
Zitieren
APA
Taprogge, J., Murray, I., Sharman, H., Gape, P., Leek, F., Abreu, C., Vávrová, L., Newbold, K., Wong, K. H., Luster, M., Verburg, F. A., Schurrat, T., Vija, L., Courbon, F., Vallot, D., Bardiès, M., Schumann, S., Eberlein, U., Lassmann, M., & Flux, G. (2025). Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-25-0097
Vancouver
Taprogge J, Murray I, Sharman H, Gape P, Leek F, Abreu C, et al. Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. European Thyroid Journal. 2025. doi:10.1530/etj-25-0097
BibTeX
@article{Taprogge2025,
author = {Taprogge, Jan and Murray, Iain and Sharman, Hannah and Gape, Paul and Leek, Francesca and Abreu, Carla and Vávrová, Lenka and Newbold, Kate and Wong, Kee H and Luster, Markus and Verburg, Frederik A and Schurrat, Tino and Vija, Lavinia and Courbon, Frédéric and Vallot, Delphine and Bardiès, Manuel and Schumann, Sarah and Eberlein, Uta and Lassmann, Michael and Flux, Glenn},
title = {Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-25-0097}
}
EUVIMED